Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Olivia Pagani(Swiss Group For Clinical Cancer Research), Prudence A. Francis(Peter MacCallum Cancer Centre), Fabio Puglisi(University of Udine), Meredith M. Regan(Dana-Farber Cancer Institute), Barbara Ruepp(The Coordinating Center), Barbara Walley, Richard D. Gelber(Harvard University), Gini F. Fleming(University of Chicago Medical Center), Carlo Tondini(Ospedale Papa Giovanni XXIII), Rudolf Maibach(The Coordinating Center), Henry Gómez(National Cancer Center), Marco Colleoni(European Institute of Oncology), Harold J. Burstein(Dana-Farber Cancer Institute), Vered Stearns(Johns Hopkins University), Hervé Bonnefoi, Charles E. Geyer(Magee-Womens Hospital), Edith A. Perez(Unknown), Diana Crivellari(Centro di Riferimento Oncologico), Manuela Rabaglio(University Hospital of Bern), Eric P. Winer(University of Vermont), Anita Giobbie‐Hurder(Institute for Tourism), Alan S. Coates(International Breast Cancer Study Group), Eva Ciruelos(Hospital Universitario 12 De Octubre), Giuseppe Viale(University of Milan), Karen N. Price(International Breast Cancer Study Group), István Láng(National Institute of Oncology), Weixiu Luo(Dana-Farber Cancer Institute), Graziella Pinotti(Medica (Italy)), Jürg Bernhard(International Breast Cancer Study Group), Aron Goldhirsch(Istituti di Ricovero e Cura a Carattere Scientifico), Karin Ribi, Silvana Martino(Angeles Clinic and Research Institute), Thomas Ruhstaller(University Hospital Bonn)
Cited by 751
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k